SCHEMBL6850822

SCHEMBL6850822

O=Cc1ccc(-c2ncno2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.42
ALDH1A1 P00352 7/20 0.36
CYP2A6 P11509 3/20 0.35
HSD17B10 Q99714 1/20 0.35
ALDH5A1 P51649 1/20 0.35
ABAT P80404 1/20 0.35
KDM4E B2RXH2 6/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
DRD1 P21728 3/20 0.34
LMNA P02545 1/20 0.34
MEN1 O00255 2/20 0.33
POLB P06746 2/20 0.33
MAPT P10636 2/20 0.33
KMT2A Q03164 2/20 0.33
IP6K1 Q92551 1/20 0.33
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD5 P21918 1/20 0.33
DRD3 P35462 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6847783 0.82 ALDH1A1 (0.43) BRD4ALDH1A1KDM4ELMNAMAPT
SCHEMBL6847776 0.82 ALDH1A1 (0.43) BRD4ALDH1A1KDM4ELMNAMAPT
SCHEMBL1175582 0.79 BRD4 (0.48) BRD4ALDH1A1CYP2A6KDM4EMEN1
SCHEMBL6854147 0.78 KDM4E (0.33) BRD4KDM4EMAPT
SCHEMBL27612729 0.74
SCHEMBL6880161 0.74
SCHEMBL17656019 0.74 NPC1 (0.50) HSD17B10SMN1; SMN2POLBNPC1RAB9A
SCHEMBL1186813 0.74 ESR1 (0.42) ALDH1A1HSD17B10SMN1; SMN2MEN1POLB
SCHEMBL6879785 0.72
SCHEMBL6879790 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1585775-A 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials ORTHO MCNEIL PHARM INC (US) 2005-02-23 CN disclosed
US-6825170-B2 ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING ORTHO-MCNEIL PHARMACEUTICAL, INC. 2004-11-30 US disclosed
EP-1453847-A1 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS Ortho-Mcneil Pharmaceutical, Inc. (US) 2004-09-08 EP disclosed
US-20030220272-A1 6-O-acyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-11-27 US disclosed
WO-2003050132-A1 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220272-A1 6-O-acyl ketolide antibacterials Q6ZSR9, ACSL6, RPS4Y1 BRD4 2037/4885ALDH1A1 2109/4885CYP2A6 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.